SG11202002186VA - Novel artificial nucleic acid molecules - Google Patents
Novel artificial nucleic acid moleculesInfo
- Publication number
- SG11202002186VA SG11202002186VA SG11202002186VA SG11202002186VA SG11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- acid molecules
- artificial nucleic
- novel artificial
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017076741 | 2017-10-19 | ||
| EP2017076775 | 2017-10-19 | ||
| PCT/EP2018/057552 WO2018172556A1 (en) | 2017-03-24 | 2018-03-23 | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP2018076185 | 2018-09-26 | ||
| PCT/EP2018/078453 WO2019077001A1 (en) | 2017-10-19 | 2018-10-17 | NEW ARTIFICIAL NUCLEIC ACID MOLECULES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002186VA true SG11202002186VA (en) | 2020-05-28 |
Family
ID=66173912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002186VA SG11202002186VA (en) | 2017-10-19 | 2018-10-17 | Novel artificial nucleic acid molecules |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220233568A1 (de) |
| EP (1) | EP3697912A1 (de) |
| JP (2) | JP2021501572A (de) |
| KR (1) | KR20200071081A (de) |
| CN (1) | CN111630173A (de) |
| AU (1) | AU2018351481A1 (de) |
| BR (1) | BR112020004351A2 (de) |
| CA (1) | CA3073634A1 (de) |
| IL (1) | IL272850A (de) |
| MX (1) | MX2020003995A (de) |
| RU (1) | RU2020115287A (de) |
| SG (1) | SG11202002186VA (de) |
| WO (1) | WO2019077001A1 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2841572B1 (de) | 2012-04-27 | 2019-06-19 | Duke University | Genetische korrektur mutierter gene |
| MX2015010880A (es) | 2013-02-22 | 2015-12-03 | Curevac Gmbh | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. |
| US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
| DK3319622T3 (da) | 2015-12-22 | 2020-05-04 | Curevac Ag | Fremgangsmåde til fremstilling af rna-molekylesammensætninger |
| US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
| SG10202110491PA (en) | 2017-03-24 | 2021-11-29 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| JP2021502079A (ja) | 2017-11-08 | 2021-01-28 | キュアバック アーゲー | ＲＮＡ配列の適合（Ａｄａｐｔａｔｉｏｎ） |
| WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
| WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
| EP3781591A1 (de) * | 2018-04-17 | 2021-02-24 | CureVac AG | Neuartige rsv-rna-moleküle und zusammensetzungen zur impfung |
| CN110241116B (zh) * | 2019-05-21 | 2023-02-07 | 中国医学科学院放射医学研究所 | 一种环状rna及在促进dna损伤修复中的应用 |
| EP3986452A1 (de) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus-mrna-impfstoff |
| AU2020328855A1 (en) | 2019-08-14 | 2022-03-03 | CureVac SE | RNA combinations and compositions with decreased immunostimulatory properties |
| JP2022546417A (ja) * | 2019-08-29 | 2022-11-04 | チューリッヒ大学 | 最小ｍＲＮＡおよびその使用 |
| CN110592223B (zh) * | 2019-10-31 | 2022-10-25 | 中南大学湘雅三医院 | 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用 |
| CN112759652B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN114929288A (zh) * | 2019-11-07 | 2022-08-19 | 西奈山伊坎医学院 | 合成的修饰的rna及其用途 |
| CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
| CA3160511A1 (en) | 2020-02-04 | 2021-08-12 | Susanne RAUCH | Coronavirus vaccine |
| WO2021158996A1 (en) * | 2020-02-05 | 2021-08-12 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| EP4126030A1 (de) * | 2020-04-01 | 2023-02-08 | University Of Florida Research Foundation, Incorporated | Multilamellarer rna-nanopartikelimpfstoff gegen sars-cov-2 |
| CN111413498B (zh) * | 2020-04-08 | 2023-08-04 | 复旦大学附属中山医院 | 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用 |
| CA3170740A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| CN111744019B (zh) * | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
| US20220017971A1 (en) * | 2020-07-15 | 2022-01-20 | Kookmin University Industry Academy Cooperation Foundation | Composition for predicting chemotherapy resistance of ovarian cancer and use thereof |
| EP4172194A1 (de) | 2020-07-31 | 2023-05-03 | CureVac SE | Nukleinsäurecodierte antikörpermischungen |
| EP4192958A4 (de) * | 2020-08-07 | 2024-08-28 | Univ Hong Kong Science & Tech | Zusammensetzungen und verfahren zur erhöhung der proteinexpression |
| CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| EP4225448A1 (de) * | 2020-10-09 | 2023-08-16 | Duke University | Neue targets zur reaktivierung von mit dem prader-willi-syndrom assoziierten genen |
| CN112280750B (zh) * | 2020-10-22 | 2022-11-01 | 山东农业大学 | 具有跨种传播能力的新型鹅星状病毒及其应用 |
| CN112526127B (zh) * | 2020-10-28 | 2022-12-06 | 四川大学华西医院 | 一种破伤风抗原的检测方法及其应用 |
| WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| JP2024502210A (ja) | 2020-12-22 | 2024-01-17 | キュアバック エスイー | ＳＡＲＳ－ＣｏＶ－２バリアントに対するＲＮＡワクチン |
| CN112574997B (zh) * | 2021-01-17 | 2023-07-21 | 楷拓生物科技(苏州)有限公司 | 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用 |
| WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| JP2024508707A (ja) * | 2021-02-12 | 2024-02-28 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 熱ショックタンパク質９０結合ドメインを有する活性誘導型融合タンパク質 |
| WO2022200574A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| CA3171429A1 (en) | 2021-03-31 | 2022-09-30 | Alexander SCHWENGER | Syringes containing pharmaceutical compositions comprising rna |
| CN113341152B (zh) * | 2021-04-27 | 2022-04-26 | 华南农业大学 | Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用 |
| WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
| EP4377331A2 (de) | 2021-07-30 | 2024-06-05 | CureVac SE | Mrnas zur behandlung oder prophylaxe von lebererkrankungen |
| EP4392140A1 (de) | 2021-08-24 | 2024-07-03 | BioNTech SE | In vitro transkriptionstechnologien |
| CA3230056A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| CA3230031A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| CN115029349A (zh) * | 2022-06-09 | 2022-09-09 | 中国农业大学 | 与植物抗病性相关的circRNA、来源基因及其应用 |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| CN115606550B (zh) * | 2022-10-28 | 2024-01-12 | 陆华 | 一种自身免疫性甲状腺炎诱导的卵巢储备功能低下动物模型的构建方法 |
| US20240156949A1 (en) | 2022-10-28 | 2024-05-16 | Glaxosmithkline Biologicals Sa | Nucleic Acid Based Vaccine |
| WO2024098360A1 (zh) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| CN116240175B (zh) * | 2023-02-28 | 2024-02-23 | 武汉科技大学 | 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用 |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CA2258125C (en) | 1996-06-14 | 2010-11-23 | Meiji Milk Products Co., Ltd. | T-cell epitope peptides |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| WO2001008636A2 (en) | 1999-08-03 | 2001-02-08 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| ES2340532T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo. |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| EP2046954A2 (de) | 2006-07-31 | 2009-04-15 | Curevac GmbH | Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans |
| DK2476436T3 (en) | 2006-08-11 | 2018-02-05 | Life Sciences Res Partners Vzw | Immunogenic peptides and their use in immune disorders |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| EP3100718B1 (de) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren |
| MX2010008468A (es) | 2008-01-31 | 2010-08-30 | Curevac Gmbh | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| PL2350043T3 (pl) | 2008-10-09 | 2014-09-30 | Tekmira Pharmaceuticals Corp | Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| CA3006395C (en) | 2008-11-07 | 2022-05-31 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| EP3808177A1 (de) | 2008-11-10 | 2021-04-21 | Arbutus Biopharma Corporation | Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika |
| WO2010087791A1 (en) | 2009-01-27 | 2010-08-05 | Utc Power Corporation | Distributively cooled, integrated water-gas shift reactor and vaporizer |
| CA3036963A1 (en) | 2009-01-29 | 2010-08-05 | Arbutus Biopharma Corporation | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
| EP2416760A4 (de) | 2009-05-05 | 2014-01-22 | Tekmira Pharmaceuticals Corp | Fettzusammensetzungen |
| PL3431076T3 (pl) | 2009-06-10 | 2022-01-31 | Arbutus Biopharma Corporation | Ulepszona formulacja lipidowa |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CN104971672B (zh) | 2010-04-09 | 2018-01-02 | 帕西拉制药有限公司 | 用于配制大直径合成膜囊泡的方法 |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| EP3449910A1 (de) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Kationische öl-in-wasser emulsionen |
| PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
| CN103025876A (zh) | 2010-07-30 | 2013-04-03 | 库瑞瓦格有限责任公司 | 用于转染和免疫刺激的核酸与二硫化物交联的阳离子成分的复合体 |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| US20130189351A1 (en) | 2010-08-31 | 2013-07-25 | Novartis Ag | Lipids suitable for liposomal delivery of protein coding rna |
| ES2938866T3 (es) | 2010-08-31 | 2023-04-17 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
| PL4008357T3 (pl) | 2010-08-31 | 2023-03-06 | Glaxosmithkline Biologicals Sa | Małe liposomy do dostarczania rna kodującego immunogen |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| EP2729126B1 (de) | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomen mit nützlichem n:p-verhältnis zur freisetzung von rna-molekülen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| US9683233B2 (en) * | 2012-03-27 | 2017-06-20 | Curevac Ag | Artificial nucleic acid molecules for improved protein or peptide expression |
| US10080809B2 (en) * | 2012-03-27 | 2018-09-25 | Curevac Ag | Artificial nucleic acid molecules comprising a 5′TOP UTR |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| MX2015010880A (es) | 2013-02-22 | 2015-12-03 | Curevac Gmbh | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. |
| KR20160043103A (ko) | 2013-08-21 | 2016-04-20 | 큐어백 아게 | 전립선암 치료를 위한 조성물 및 백신 |
| AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
| BR112016003400A2 (pt) | 2013-08-21 | 2017-12-05 | Curevac Ag | composição e vacina para tratamento de câncer de pulmão |
| MX369469B (es) | 2013-08-21 | 2019-11-08 | Curevac Ag | Vacuna contra el virus respiratorio sincitial. |
| CN111304231A (zh) * | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| EP3116535B1 (de) | 2014-03-12 | 2019-08-07 | CureVac AG | Kombination von impfstoffen und ox40-agonisten |
| EP3129050A2 (de) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymerträger-cargo-komplex zur verwendung als immunstimulierendes mittel oder als ein adjuvans |
| CA2962849A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| JP6907116B2 (ja) * | 2014-12-30 | 2021-07-21 | キュアバック アーゲー | 人工核酸分子 |
| ES2753259T3 (es) | 2015-04-22 | 2020-04-07 | Curevac Ag | Composición que contiene ARN para el tratamiento de enfermedades tumorales |
| US20190017100A1 (en) * | 2015-07-01 | 2019-01-17 | Curevac Ag | Method for analysis of an rna molecule |
| SG10201913629VA (en) * | 2015-08-28 | 2020-03-30 | Curevac Ag | Artificial nucleic acid molecules |
| WO2017081082A2 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
| US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
| DK3319622T3 (da) | 2015-12-22 | 2020-05-04 | Curevac Ag | Fremgangsmåde til fremstilling af rna-molekylesammensætninger |
| BR112018016755A2 (pt) | 2016-02-17 | 2018-12-26 | Curevac Ag | vacina contra o vírus da zica |
| WO2018104540A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| SG10202110491PA (en) * | 2017-03-24 | 2021-11-29 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
-
2018
- 2018-10-17 SG SG11202002186VA patent/SG11202002186VA/en unknown
- 2018-10-17 CA CA3073634A patent/CA3073634A1/en active Pending
- 2018-10-17 EP EP18789606.3A patent/EP3697912A1/de active Pending
- 2018-10-17 MX MX2020003995A patent/MX2020003995A/es unknown
- 2018-10-17 WO PCT/EP2018/078453 patent/WO2019077001A1/en unknown
- 2018-10-17 AU AU2018351481A patent/AU2018351481A1/en active Pending
- 2018-10-17 US US16/757,289 patent/US20220233568A1/en active Pending
- 2018-10-17 CN CN201880067696.6A patent/CN111630173A/zh active Pending
- 2018-10-17 KR KR1020207012300A patent/KR20200071081A/ko not_active Application Discontinuation
- 2018-10-17 JP JP2020521986A patent/JP2021501572A/ja active Pending
- 2018-10-17 BR BR112020004351-6A patent/BR112020004351A2/pt unknown
- 2018-10-17 RU RU2020115287A patent/RU2020115287A/ru unknown
-
2020
- 2020-02-23 IL IL272850A patent/IL272850A/en unknown
-
2023
- 2023-11-06 JP JP2023189376A patent/JP2024012523A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018351481A1 (en) | 2020-03-12 |
| JP2024012523A (ja) | 2024-01-30 |
| CN111630173A (zh) | 2020-09-04 |
| BR112020004351A2 (pt) | 2020-09-08 |
| KR20200071081A (ko) | 2020-06-18 |
| CA3073634A1 (en) | 2019-04-25 |
| WO2019077001A1 (en) | 2019-04-25 |
| EP3697912A1 (de) | 2020-08-26 |
| RU2020115287A (ru) | 2021-11-19 |
| IL272850A (en) | 2020-04-30 |
| MX2020003995A (es) | 2020-07-22 |
| US20220233568A1 (en) | 2022-07-28 |
| RU2020115287A3 (de) | 2022-02-28 |
| JP2021501572A (ja) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272850A (en) | Artificial nucleic acid molecules | |
| SG11201911430PA (en) | Novel nucleic acid molecules | |
| SG10201913629VA (en) | Artificial nucleic acid molecules | |
| SG11201704681QA (en) | Artificial nucleic acid molecules | |
| IL278000B (en) | Synthetic nucleic acid transcripts | |
| PL3708668T3 (pl) | Sztuczne cząsteczki kwasu nukleinowego dla poprawy ekspresji białka | |
| IL272463A (en) | Nucleic acid molecules and their uses | |
| IL254000A0 (en) | Nucleic acid sequence composition | |
| EP3157573A4 (de) | Alternative nukleinsäuremoleküle und verwendungen davon | |
| EP3157572A4 (de) | Alternative nukleinsäuremoleküle und verwendungen davon | |
| SG11201603144QA (en) | Artificial nucleic acid molecules | |
| SG11201610168YA (en) | Nucleic acid synthesis techniques | |
| GB201507119D0 (en) | Nucleic Acid Construct | |
| HK1243958A1 (zh) | 核酸構建體 | |
| HK1244021A1 (zh) | 核酸構建體 | |
| GB201507115D0 (en) | Nucleic Acid Construct | |
| LT3094731T (lt) | Sacharidais modifikuotos nukleorūgšties molekulės | |
| GB201507111D0 (en) | Nucleic acid construct | |
| IL277472A (en) | Nucleic acid molecules for pseudouridylation | |
| ZA202001649B (en) | Rna molecules | |
| GB201812474D0 (en) | Nucleic acid construct | |
| GB201617548D0 (en) | Novel biological factor | |
| EP3351251A4 (de) | Nukleinsäuremolekül | |
| GB201704685D0 (en) | Biological methods | |
| GB201613839D0 (en) | Novel nucleic acid construct |